Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

3533Background: Utilization of ctDNA has been rapidly adopted as a predictive diagnostic in advanced Non-Small Cell Lung Cancer and indications in GI cancers may be emerging. We aimed to evaluate c...